What this site is — and what it is not.

The editorial mandate

Reviews Retatrutide is an independent editorial project that publishes summaries and appraisals of the peer-reviewed research literature on retatrutide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain modifier — "reviews" — reflects the editorial stance of this publication: critical, evidence-grounded appraisal of the clinical trial record, study by study. It does not describe a service, a review platform, or a clinical function. This site does not collect user reviews, does not host patient testimonials, and does not aggregate product ratings. It appraises published evidence.

Retatrutide is an investigational compound studied by Eli Lilly. It is not approved by the FDA or any regulatory agency as of mid-2026. This site documents what the published trial record contains — not what vendors claim about unregulated research-labeled material.

What this dossier covers

The primary lens of this dossier is retatrutide's effects on liver disease — specifically MASLD (metabolic dysfunction-associated steatotic liver disease, formerly called NAFLD), for which the Phase 2 data are the most striking: −82.4% liver-fat reduction and 86% of participants reaching normal liver fat in the 48-week MASLD substudy published in Nature Medicine ^[5]. The dossier also covers the full obesity and type 2 diabetes Phase 2 record, the cryo-EM structural work confirming triple-receptor engagement, Phase 3 trial design and open questions, and the community-reported effects layer.

All content is drawn from published, peer-reviewed literature. Citations are numbered and linked throughout the site. No claim is made without a source study behind it.

Editorial standards

This site does not accept advertising, affiliate revenue, or sponsored content. It does not sell any product and has no commercial relationship with Eli Lilly, any clinical research organization, or any peptide vendor.

All quantitative claims are cited inline. Disputed or uncertain claims are labeled as such. The community-reported effects layer on the Retatrutide effects page is explicitly labeled as anecdotal — not clinical evidence — because it is. Plain-English summaries are present on every content page to make the research accessible to non-specialist readers; technical depth is preserved alongside, not instead of, those summaries.

This site uses no tracking cookies, no advertising scripts, and no analytics beyond standard Cloudflare edge logs.